Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 126Cisplatin 48Cetuximab 46Nivolumab 36Carboplatin 33Paclitaxel 28Fluorouracil 26Docetaxel 17Cyclophosphamide 12avelumab 11Radiotherapy 11cemiplimab 10atezolizumab 10durvalumab 9Ipilimumab 8spartalizumab 7fludarabine 7budigalimab 7Gemcitabine 7Capecitabine 7tremelimumab 6lenvatinib 6Pemetrexed 6130-nm albumin-bound paclitaxel 6epacadostat 5Fulvestrant 5zimberelimab 4tislelizumab 4Trastuzumab 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Carcinoma of Head and Neck × STX-478 × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡